Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Building R&D Capabilities In China – Spotlight On Pfizer

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Multinational pharmaceutical companies have moved beyond debating whether to open R&D operations in China to debating whether to open "brick and mortar" operations or "virtual" operations via outsourcing, according to speakers at the China 2008 Pharmaceutical R&D Summit in Shanghai
Advertisement

Related Content

Big Pharma Stretches To Reshape Itself To Enter Asia With Flexible, Multiple-Partner Networks – Singapore Conference
Big Pharma Stretches To Reshape Itself To Enter Asia With Flexible, Multiple-Partner Networks – Singapore Conference
GSK Jumps Into Growing China R&D Space
GSK Jumps Into Growing China R&D Space
Advertisement
UsernamePublicRestriction

Register

SC067852

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel